Table 6.
Phytoconstituents/Herbal medicines | Type | Mode of action | Proposed therapeutic against | Model | References |
---|---|---|---|---|---|
Caflanone, Equivir, Hesperetin, Myricetin and Linebacker | Flavonoid | Bind to spike protein, helicase and protease sites on ACE2 receptor with high affinity | SARS-CoV-2 | In silico | Stebbing et al. (2020) |
Astragali Radix (Huangqi), Glycyrrhizae Radix Et Rhizoma (Gancao), Saposhnikoviae Radix (Fangfeng), Atractylodis Macrocephalae Rhizoma (Baizhu), and Lonicerae Japonicae Flo | Traditional Chinese Medicines | Majorly by inhibiting inflammation condition associated with COVID-19 | SARS-CoV-2 | Recommendations as per Chinese guidelines and official government websites of 31 provinces in mainland China | Cunningham et al. (2020) |
Luteolin | Flavonoid | Alleviates NLRP3 inflammasome activation | SARS-CoV | In vitro | Kalil (2020) |
Myricetin | Flavonoid | Inhibits NLRP3 inflammasome activation | SARS-CoV | In vivo | Badri et al. (2021) |
Apigenin | Flavonoid | Reduces induction of LOX-1 and NLRP3 expression | SARS-CoV | In vitro | Girija and Sivan (2020) |
Quercetin | Flavonoid | Suppresses fructose-induced NLRP3 inflammasome activation | SARS-CoV | In vitro | Ang et al. (2020) |
Kaempferol | Flavonoid | Interferes with NLRP3 inflammasome activation | SARS-CoV | In vivo | Du et al. (2020) |
Baicalin | Flavonoid | Suppresses NLRP3 inflammasome and NF-κB signaling |
SARS-CoV Dengue viral infection |
Ex vivo and in vitro | Ren et al. (2020) |
Wagonoside | Flavonoid | Inhibit NF-κB signaling and NLRP3 inflammasome | SARS-CoV | In vivo | Du et al. (2020) |
Apigenin, Luteolin, Kaempferol, Quercetin, Isorhamnetin, Formononetin, Chrysosplenetin and Penduletin |
Flavonoids | Undisclosed | Enterovirus 71 | In silico | |
Emodin | Anthraquinone | Inhibit interaction of SARS-CoV spike protein with ACE2 receptor | SARS-CoV | In vitro |
Ni et al. (2020) Kremsner et al. (2020) |
Resveratrol | Stilbenoid | Inhibition of viral replication and host cell apoptosis along with prolonging cellular survival after viral infection | MERS-CoV | In vitro |